Central Nervous System Neoplasms, Primary Clinical Trial
Official title:
Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma
This study will compare the overall survival (OS) time of elderly patients who would not
tolerate standard chemotherapy for PCNSL treated with WBXRT together with Optune-TTF to those
treated with whole-brain radiotherapy alone.
Standard treatment of primary central nervous system lymphoma (PCNSL) for patients with good
performance status involves high-dose methotrexate-based chemotherapy regimens and
whole-brain radiation therapy (WBXRT). Although up to 20% of patients with PCNSL are 80 years
of age or older, little data exist with regard to optimal treatment of this patient
population and they often do not qualify for clinical trials. In addition, elderly patients
have a poorer rate of complete and partial response and increased risk of toxicity when
treated with standard chemotherapy regimens. Though a consensus does not exist, radiotherapy
alone is often used in these patients to minimize toxic effects of more aggressive
chemotherapies.
The Optune TTF device has proven effective in treating high-grade gliomas and is currently
being investigated to treat meningiomas and metastatic lesions in the brain as well as other
tumor types elsewhere in the body. It is generally well tolerated with no known systemic side
effects, producing only an occasional local skin reaction. The mechanism of action is
independent of tumor type and therefore may be effective in treating lymphoma as well.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT04446962 -
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
|
Phase 1/Phase 2 |